SCHEMBL12200293

SCHEMBL12200293

OCC[C@H](c1ccccc1)c1cc(CO)ccc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.46
CHRM1 P11229 3/20 0.46
CHRM3 P20309 3/20 0.46
LMNA P02545 3/20 0.46
CHRM5 P08912 2/20 0.46
HRH1 P35367 2/20 0.46
MAPT P10636 2/20 0.46
ESR1 P03372 1/20 0.46
CHRM4 P08173 1/20 0.46
KCNE1 P15382 1/20 0.46
PTGS1 P23219 1/20 0.46
HRH2 P25021 1/20 0.46
HTR2A P28223 1/20 0.46
SLC6A4 P31645 1/20 0.46
ADRA1A P35348 1/20 0.46
OPRK1 P41145 1/20 0.46
KCNQ1 P51787 1/20 0.46
KCNH2 Q12809 1/20 0.46
CACNA1C Q13936 1/20 0.46
SCN5A Q14524 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15492087 0.88 LMNA (0.47) CHRM2CHRM1CHRM3LMNACHRM5
SCHEMBL11294062 0.88 HRH1 (0.50) CHRM2CHRM1CHRM3LMNACHRM5
SCHEMBL6459390 0.88 HRH1 (0.50) CHRM2CHRM1CHRM3LMNACHRM5
SCHEMBL580184 0.82 MEN1 (0.47) CHRM2CHRM1CHRM3LMNACHRM5
SCHEMBL580170 0.82 MEN1 (0.47) CHRM2CHRM1CHRM3LMNACHRM5
Desfesoterodine SCHEMBL29468683 0.82 CHRM3 (0.72) CHRM2CHRM1CHRM3LMNACHRM5
Desfesoterodine SCHEMBL816124 0.82 CHRM3 (0.72) CHRM2CHRM1CHRM3LMNACHRM5
SCHEMBL580169 0.82 MEN1 (0.47) CHRM2CHRM1CHRM3LMNACHRM5
Desfesoterodine SCHEMBL580657 0.82 CHRM3 (0.72) CHRM2CHRM1CHRM3LMNACHRM5
Desfesoterodine SCHEMBL209062 0.82 CHRM3 (0.72) CHRM2CHRM1CHRM3LMNACHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742140-B2 Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof UCB PHARMA GMBH (DE) 2014-06-03 US disclosed
US-8742140-B2 Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof UCB PHARMA GMBH (DE) 2014-06-03 US disclosed
EP-2027103-B1 NEW CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF UCB PHARMA GMBH (DE) 2014-02-26 EP disclosed
US-20110245338-A1 CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF UCB PHARMA GMBH (DE) 2011-10-06 US disclosed
US-20110245338-A1 CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF UCB PHARMA GMBH (DE) 2011-10-06 US disclosed
US-7982058-B2 Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof UCB PHARMA GMBH (DE) 2011-07-19 US disclosed
US-7982058-B2 Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof UCB PHARMA GMBH (DE) 2011-07-19 US disclosed
US-20090192224-A1 CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF SCHWARZ PHARMA AG (DE) 2009-07-30 US disclosed
US-20090192224-A1 CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF SCHWARZ PHARMA AG (DE) 2009-07-30 US disclosed
WO-2007144097-A1 NEW CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF SCHWARZ PHARMA AG (DE) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192224-A1 CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF CYP1B1, NISCH, HSD17B7 CHRM2 108/4885CHRM1 133/4885CHRM3 107/4885
US-20110245338-A1 CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF CYP1B1, NISCH, HSD17B7 CHRM2 108/4885CHRM1 133/4885CHRM3 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.